Earnings summaries and quarterly performance for SUTRO BIOPHARMA.
Executive leadership at SUTRO BIOPHARMA.
Jane Chung
Detailed
Chief Executive Officer
CEO
BL
Barbara Leyman
Detailed
Chief Business Development Officer
DP
David Pauling
Detailed
General Counsel and Chief Administrative Officer
GC
Greg Chow
Detailed
Chief Financial Officer
HG
Hans-Peter Gerber
Detailed
Chief Scientific Officer
VS
Venkatesh Srinivasan
Detailed
Chief Technical Operations Officer
Board of directors at SUTRO BIOPHARMA.
Research analysts who have asked questions during SUTRO BIOPHARMA earnings calls.
ET
Edward Tenthoff
Piper Sandler Companies
2 questions for STRO
Also covers: ARVN, ARWR, CAPR +14 more
Jay Olson
Oppenheimer & Co. Inc.
2 questions for STRO
Also covers: ACAD, AMGN, BIIB +22 more
RB
Reni Benjamin
Citizens JMP Securities
2 questions for STRO
Also covers: ALLO, BCAB, BGNE +7 more
JS
Jiale Song
Jefferies Financial Group Inc.
1 question for STRO
Also covers: ACRS, CRVS, CTMX +12 more
RS
Roger Song
Jefferies
1 question for STRO
Also covers: AADI, AKBA, ALT +13 more
Recent press releases and 8-K filings for STRO.
Sutro Biopharma Provides Pipeline and Strategic Update at J.P. Morgan Healthcare Conference
STRO
New Projects/Investments
Guidance Update
- Sutro Biopharma has undergone a strategic pivot to become a clinical oncology company, accelerating its pipeline and extending its cash runway to mid-2027.
- The company's lead program, STRO-004 (Tissue Factor ADC), is currently in a Phase 1 trial, with initial top-line data anticipated by mid-2026.
- Sutro plans to advance STRO-006 (Integrin beta-6 targeting ADC) to an IND later in 2026 and its first dual payload ADC (targeting PTK7) into the clinic by late 2026 or early 2027.
- A collaboration iADC program with Astellas Pharma is also entering the clinic early 2026, further validating Sutro's differentiated dual payload ADC technology.
2 days ago
Sutro Biopharma Provides Update on Strategic Pivot and Clinical Pipeline at J.P. Morgan Healthcare Conference
STRO
Product Launch
Guidance Update
Management Change
- Under CEO Jane Chung (since March 2025), Sutro Biopharma has completed a strategic pivot to become a clinical oncology company, accelerating its pipeline and right-sizing its operations.
- The company's lead program, STRO-004 (Tissue Factor ADC), is in Phase I with initial top-line data anticipated by mid-2026. STRO-006 is on track for an IND later this year (2026), and the first dual payload ADC (PTK7 target) is expected to enter the clinic later this year (2026) or early 2027. A partnered iADC program with Astellas Pharma is also entering the clinic early this year (2026).
- Sutro has extended its cash runway to mid-2027, excluding collaboration milestones. The company emphasizes its differentiated ADC technology, enabling the development of dual payload ADCs with improved safety and efficacy profiles.
2 days ago
Sutro Biopharma Provides Update on Strategic Pivot and ADC Pipeline at J.P. Morgan Healthcare Conference
STRO
CEO Change
New Projects/Investments
Guidance Update
- Sutro Biopharma has undergone a strategic transformation since March 2025, redefining its strategy, right-sizing its team, and focusing on becoming a clinical oncology company with a differentiated Antibody-Drug Conjugate (ADC) technology.
- The company has extended its cash runway to mid-2027, which does not include potential collaboration milestones that could further extend it. This runway supports advancing multiple programs into the clinic.
- Sutro's pipeline includes STRO-004 (Tissue Factor ADC), which entered Phase 1 clinical trials in November 2025 and is expected to deliver initial top-line data by mid-2026.
- The company is also advancing STRO-006 (Integrin beta-6 targeting ADC), on track for an Investigational New Drug (IND) application later in 2026, and a first dual payload ADC targeting PTK7, with IND entry moved up to later 2026 or early 2027.
- Sutro's dual payload ADC approach is designed to overcome resistance and improve clinical responses, with preclinical data showing these programs are well-tolerated at doses comparable to single-payload ADCs.
2 days ago
Sutro Biopharma Provides Pipeline and Financial Update at J.P. Morgan Healthcare Conference
STRO
New Projects/Investments
Product Launch
Guidance Update
- Sutro Biopharma projects its cash runway to extend into at least mid-2027, including certain expected near-term milestone payments.
- The company anticipates initial Phase 1 data for STRO-004 in mid-2026.
- IND submissions are expected for STRO-006 in 2026 and STRO-227 in 2026-2027.
- The first program from the iADC partnership with Astellas is slated to enter the clinic in early 2026.
2 days ago
Sutro Biopharma Regains Nasdaq Minimum Bid Price Compliance
STRO
Delisting/Listing Issues
- Sutro Biopharma, Inc. (STRO) announced on December 17, 2025, that it has regained compliance with the Nasdaq Stock Market's continued listing standard for minimum share price.
- The company received confirmation from Nasdaq that its common stock maintained an average closing share price of at least $1.00 as of December 16, 2025.
- This compliance was achieved following a 1:10 reverse stock split that became effective on December 3, 2025.
Dec 17, 2025, 9:05 PM
Sutro Provides Pipeline and Financial Update at Healthcare Conference
STRO
New Projects/Investments
Guidance Update
Product Launch
- Sutro announced that the first patient cohort has been dosed in the Phase 1 study for its tissue factor ADC, STRO-004, with top-line data anticipated by mid-2026.
- The company plans to file an Investigational New Drug (IND) application for its integrin beta-6 ADC (STRO-006) in 2026 and is developing a dual payload ADC (STRO-227) targeting PTK7, designed to overcome resistance to single payload ADCs.
- Sutro's cash runway has been extended into the middle of 2027, reflecting strategic efforts to reduce burn and externalize manufacturing.
- In collaboration with Astellas, Sutro is advancing an immunostimulatory ADC program, with the first program expected to enter the clinic in early 2026.
Dec 3, 2025, 8:30 PM
Sutro Biopharma Details XpressCF Platform and Clinical Pipeline Progress
STRO
New Projects/Investments
Guidance Update
- Sutro Biopharma's XpressCF platform enables the development of next-generation antibodies, including ADCs with 2-3 fold higher drug exposure and site-specific conjugation.
- The company has dosed the first cohort of patients in its Phase 1 study for STRO-004, a tissue factor ADC, and anticipates top-line data by the middle of next year (mid-2026). STRO-004 is designed for improved safety and efficacy, with a high non-severely toxic dose (HNSTD) of 50 mg/kg.
- Sutro plans to file an IND for its integrin beta-6 ADC (STRO-006) next year (2026) and is developing dual payload ADCs to overcome resistance to single payload ADCs.
- The company's partnership with Astellas is developing immunostimulatory ADCs, with Astellas' first program expected to enter the clinic early next year (2026).
- Sutro has extended its cash runway into the middle of 2027, not including potential milestones from partnerships.
Dec 3, 2025, 8:30 PM
Sutro Provides Update on XpressCF Platform, Clinical Pipeline, and Financial Runway
STRO
New Projects/Investments
Guidance Update
Product Launch
- Sutro's XpressCF platform enables next-generation ADCs with enhanced drug exposure, site-specific conjugation, and dual payloads, aiming to overcome resistance to single payload ADCs.
- The company has dosed the first cohort of patients in the Phase 1 study for its tissue factor ADC, STRO-004, with IND clearance in late October and top-line data anticipated by mid-2025.
- Sutro plans to file an IND for an integrin beta-6 ADC next year and is developing a dual payload ADC (STRO-227) targeting PTK7, designed for improved efficacy and safety.
- Sutro has extended its cash runway into mid-2027 by reducing burn and externalizing manufacturing, following a strategic pivot in March.
Dec 3, 2025, 8:30 PM
Sutro Biopharma Outlines Strategic Reset and Pipeline Advancements at 2025 R&D Day
STRO
New Projects/Investments
Management Change
Guidance Update
Nov 12, 2025, 3:00 PM
Sutro Biopharma Details Strategic Reset and Advances Differentiated ADC Pipeline at 2025 R&D Day
STRO
New Projects/Investments
Guidance Update
- Sutro Biopharma has undergone a strategic reset, focusing on a differentiated Antibody-Drug Conjugate (ADC) pipeline and has extended its cash runway to the middle of 2027.
- The lead program, STRO-004, a tissue factor ADC, is now active and enrolling in the clinic, with initial top-line data anticipated in mid-2026. Preclinical data showed a high non-severe toxic dose (HNSTD) of 50 mg/kg and anti-tumor activity at doses as low as 1 mg/kg.
- The company is advancing STRO-006, an integrin beta-6 ADC, with an Investigational New Drug (IND) filing targeted for 2026.
- Sutro is also progressing dual payload ADCs, including its first wholly-owned program targeting PTK7, aiming for clinic entry as early as 2026-2027, and an Astellas-partnered iADC program expected to enter the clinic in early 2026.
- Sutro's ADC technology is designed to optimize every component (antibody, linker, payload) to achieve improved safety and efficacy, allowing for higher drug exposure and potentially overcoming resistance.
Nov 12, 2025, 3:00 PM
Quarterly earnings call transcripts for SUTRO BIOPHARMA.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more